The novel NK3 receptor-inhibitor fezolinetant controlled vasomotor symptoms of menopause over 52 weeks in the phase 3 SKYLIGHT 2 trial.
Medscape Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *